Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446998 · ClinicalTrials.gov registry record · Phase 2
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
A Phase 2 study, sponsored by Veru.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07446998: Recruiting Phase 2 study, sponsored by Veru.
NCT07446998 is a Phase 2 study that is actively recruiting participants, run by Veru. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07446998, a Phase 2 study, is actively recruiting participants, sponsored by Veru.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the effect of enobosarm on total body weight
Primary Outcome
To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.
Interventions
- DRUG Enobosarm
- DRUG Semaglutide (Wegovy) weekly injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT07446998 shows while recruiting
NCT07446998 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 2 interventions - of which Enobosarm is the first listed.
NCT07446998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07446998 about?
NCT07446998 is a clinical study titled "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss". The primary objective of this study is to assess the effect of enobosarm on total body weight
What is the current status of trial NCT07446998?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-03-26. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07446998?
The interventions under investigation include: Enobosarm (DRUG), Semaglutide (Wegovy) weekly injection (DRUG).
Who is sponsoring clinical trial NCT07446998?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07446998's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI